Max Healthcare Institute runs a network of hospitals across Delhi, Uttar Pradesh, Maharashtra and Punjab, and heads into its Q2 FY 2026-2027 print with margins under scrutiny after Q1 FY27 EBITDA margin slipped to 24.8% from 26.8% in Q4 FY26. The quarter will speak to whether the Max Smart Saket bed handover and brownfield bed-fill restore margins above 25%, and how the Kalinga Hospital integration and rising finance costs shape the PAT trajectory.
| Results date | October 30, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 2,982 Cr (Network gross revenue, +16% YoY) |
| Previous quarter PAT | Rs. 357 Cr (Network PAT, +3% YoY) |
| Previous quarter EBITDA margin | 24.8% |
| Net debt (latest quarter) | Rs. 2,384 Cr (June 2026) |
| Market cap | Rs. 80,186.17 Cr |
| CMP | Rs. 823.85 |
The Board meets on October 30, 2026 to approve the Q2/H1 FY27 (September 30, 2026) unaudited financial results. The trading window remains closed till 48 hours after the results are announced.
The Q2/H1 FY27 earnings call is scheduled for November 3, 2026 at 12:00 Noon IST.
The big question for this quarter is whether operating margin recovers toward management's stated ability to sustain above 25% EBITDA margins on the expanded footprint, after Q1 FY27 printed at 24.8% with Rs. 195 Cr of indirect overheads from new units including Kalinga. The recovery levers management pointed to are the remaining 198 beds of the Max Smart Saket tower handing over to Operations in Q2 FY27 and brownfield bed-fill at Mohali and Nanavati, where margins of ~39% and ~31% were already EBITDA-accretive. On demand, Delhi's dengue tally reached 597 cases by September 26, 2026 with September alone adding 286 dengue and 124 malaria cases, a normal seasonal build that is nonetheless below the corresponding 2025 cumulative level, so the vector-borne tailwind to Internal Medicine and Pediatrics admissions is muted year-on-year. The CGHS/oncology pricing fault-line stays live: the residual Rs. 30-40 Cr of the Rs. 140 Cr net annual CGHS benefit is still to flow, and the NPPA's cap on trade margins of 137 anti-cancer drugs at 30% of MRP takes effect November 9, 2026, tightening rather than reversing the institutional oncology pricing environment. Below EBITDA, finance costs of Rs. 71.0 Cr (+29.4% YoY in Q1) on net debt of Rs. 2,384 Cr, with the 10-year G-Sec at 7.05% by September 21 and a post-quarter repo hike to 5.50%, mean the depreciation and finance-cost drag on PAT does not ease this print. The call will likely cover the margin bridge, Kalinga's occupancy ramp from 50% toward the network's above-75% level, and the status of the Alps Hospital GST notice of Rs. 55.24 Cr.
Margin trajectory vs the above-25% claim: Q1 FY27 margin of 24.8% sits below management's stated ability to sustain above 25% EBITDA margins on the expanded footprint.
Guidance scorecard
Kalinga integration and strategic initiatives
Risk follow-ups: GST notice, NCLT and CGHS policy
Operating metrics and the high base
Network PAT grew 3% YoY against 16% revenue growth in Q1 FY27, primarily due to higher depreciation and finance costs following commissioning of brownfield capacity expansion at MSSH Mohali, Nanavati-Max and Max Smart. Finance costs rose 29.4% YoY to Rs. 71.0 Cr and depreciation rose 26.4% YoY to Rs. 131.7 Cr.
The Sector-56 Gurgaon 500-bed greenfield was originally guided for commissioning by end FY27, but management flagged a minor delay of a few months due to labour shortages and logistical challenges, with opening now expected by the end of the second half. FY'28 breakeven is targeted via a phased rollout starting with around 200 beds.
Management declined to quantify the EBITDA drag from new hospitals, explaining that patient mingling between old and new towers makes segment-level separation impossible, while confirming no consolidated margin pressure. This remains an open quantification gap analysts have flagged.
The company had 6,100+ operational beds as of June 30, 2026 against the 8,000-bed target by FY'28, with 645 bed additions and Rs. 1,637 Cr of capex outflow planned for FY27. Management has stated it does not open beds without occupancy and has seen a very good ramp-up at brownfield additions.
Management attributed doctor cost inflation to the 20-25% capacity expansion across Dwarka, Jaypee, Sahara, Alexis (Nagpur), Mohali, Nanavati, Smart and Lucknow. It expects operating leverage to lower doctor fees as a percentage of revenue and noted such costs are typically passed through to patients.